Liste complète

Photo by Hope House Press on UnsplashPublications dans Google Scholar  et PubMed

Plus de 90 publications: Premier auteur: 19; Dernier auteur: 27; Second auteur: 12

  1. Audinot V, Bréard J, Chevalier L, Cussac D, Kordon C (1992). G protein mediated processes in neuroendocrine and neuroimmune interactions. Prog. NeuroEndocrinImmunology 5:1-12. Review
  2. Cussac D, Caccavelli L, Pellegrini I, Audinot V, Jaquet P, Enjalbert A (1993). Membrane receptors and coupling proteins in adenohypophyseal cells. C. R. Soc. Biol. 187:14-23. Review
  3. Cussac D, Kordon C, Enjalbert A, Saltarelli D (1993). VIP induced cross-talk between G proteins in membranes from anterior pituitary cells. Cellular Signalling 5:119-137.
  4. Cussac D, Frech M, Chardin P (1994). Binding of the Grb2 SH2 domain to phosphotyrosine motifs does not change the affinity of its SH3 domains for Sos proline-rich motifs. EMBO J. 13:4011-4021.
  5. Chardin P, Cussac D, Maignan S, Ducruix A (1995). The Grb2 adaptor. FEBS Letters 369, 47-51. Review
  6. Frech M, Cussac D, Chardin P, Bar-Sagi D (1995). Purification of the guanine nucleotide exchange factor HSos 1. Methods in Enzymology 255 Small GTPases and their regulators, Part A, Ras family edited by W.E. Balch, Channing J. Der, Alan Hall.
  7. Cussac D, Kordon C, Enjalbert A, Saltarelli D (1996). ADP-ribosylation of Gi and Go in pituitary cells enhances their recognition by antibodies directed against their carboxyl termini. Journal of Receptor and Signal Transduction Research 16(3&4):169-190.
  8. Cussac D, Leblanc P, L’Héritier A, Bertoglio J, Lang P, Kordon C, Enjalbert A, Saltarelli D (1996). Rho proteins are localized with different membrane compartments involved in vesicular trafficking in anterior pituitary cells. Mol. Cell. Endo. 119:195-206.
  9. Popoff MR, Chaves-Olarte E, Giry M, von Eichel-Streiber C, Thelestam M, Chardin P, Cussac D, Antonny B, Flatau G, Lemichez E, Chavrier P, Boquet P (1996). Clostridium sordellii lethal toxin (LT) is a glucosyltransferase which glucosylates the ras GTPase on threonine 35. J. Biol. Chem. 271:10217-10224.
  10. Montiel JL, Cussac D, Cornille F, Vidal M, Garbay C, Roques BP (1997). Rapid and efficient purification of rat brain dynamin using an affinity column of the carboxy-terminal SH3 domain of Grb2. Protein and Peptide Letters 4(3):195-202.
  11. Leprince C, Romero F, Cussac D, Vayssiere B, Berger R, Tavitian A, Camonis J (1997). A new member of the amphiphysin family connecting endocytosis and signal transduction pathways. J. Biol. Chem. 272:15101-15105.
  12. Cornille F, Martin L, Lenoir C, Cussac D, Roques BP, Fournié-Zaluski MC (1997) Cooperative exosite-dependent cleavage of synaptobrevin by tetanus toxin L-chain J. Biol. Chem. 272:3459-3464.
  13. Vidal M, Montiel JL, Cussac D, Cornille F, Duchesne M, Parker F, Tocqué B, Roques BP, Garbay C (1998). Differential interactions of the Growth Factor Receptor-bound Protein 2 N-SH3 domain with Son of Sevenless and Dynamin: Role in the ras-dependent signaling pathway. J. Biol. Chem. 273:5343-5348.
  14. Cussac D, Vidal M, Leprince C, Liu WQ, Cornille F, Tiraboschi G, Roques BP, Garbay C (1999). A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity. FASEB J. 13:31-39.
  15. Vidal M, Goudreau N, Cornille F, Cussac D, Gincel E, Garbay C (1999). Molecular and cellular analysis of Grb2 SH3 domain mutants : Interaction with Sos and Dynamin. J. Mol. Biol. 290:717-730.
  16. Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G (1998). S 16924 ((+)-2-{1-[2-(2,3-dihydro-benzo [1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl) ethanone), a novel, potential antipsychotic with marked serotonin (5 HT)1A agonist properties. I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286:1341-1355.
  17. Newman-Tancredi A*, Cussac D* (* These two authors have made equivalent contributions), Audinot V, Pasteau V, Gavaudan S, Millan MJ (1999). G-protein activation by human dopamine D3 receptors in high-expressing Chinese Hamster Ovary cells: a guanosine-5-O-(3-[35S]thio) Triphosphate binding and antibody study. Molecular Pharmacology 55:564-574.
  18. Cussac D, Newman-Tancredi A, Pasteau V, Millan MJ (1999). Human dopamine D3 receptors mediate Mitogen-Activated Protein kinase activation via a phosphatidylinositol 3-kinase and an atypical Protein kinase C-dependent mechanism. Molecular Pharmacology 56:1025-1030.
  19. Newman-Tancredi A, Cussac D, Audinot V, Millan MJ (1999). Actions of roxindole at recombinant humen dopamine D2 , D3 and D4 and serotonin 5-HT1A , 5 HT1B , 5-HT1D receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 359:447-453.
  20. Dubuffet T, Newman-Tancredi A, Cussac D, Audinot V, Loutz A, Millan MJ, Lavielle G (1999). Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonists. Bioorg. Med. Chem. Lett. 9:2059-2064.
  21. Cussac D, Newman-Tancredi A, Sezgin L, Millan MJ (2000). [3H]S33084 : a novel, selective and potent radioligand at cloned, human dopamine D3 receptors Naunyn-Schmiedeberg’s Arch. Pharmacol. 361:569-572.
  22. Cussac D, Newman-Tancredi A, Sezgin L, Millan MJ (2000). The novel antagonist, S33084 , and GR218,231 interact selectively with cloned and native, rat dopamine D3 receptors as compared with native, rat dopamine D2 receptors Eur. J. Pharmacol. 394:47-50.
  23. Cussac D, Newman-Tancredi A, Quentric Y, Millan MJ (2000). An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [3H]phosphatidylinositol depletion. Naunyn-Schmiedeberg’s Arch. Pharmacol. 361:221-223.
  24. Cussac D, Newman-Tancredi A, Nicolas JP, Boutin JA, M.J. Millan (2000). Antagonist properties of the novel antipsychotic, S 16924, at cloned, human serotonin 5 HT2C receptors : a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol. Naunyn-Schmiedeberg’s Arch. Pharmacol. 361:549-554.
  25. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Cogé F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A (2000). Agonist and antagonist actions of yohimbine as compared to fluparoxan at 2-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D, dopamine D2 and D3 receptors : significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35:79-95.
  26. Millan MJ, Dekeyne A, Newman-Tancredi A, Cussac D, Audinot V, Milligan G, Duqueyroix D, Girardon S, Mullot J, Boutin JA, Nicolas JP, Renouard-Try A, Lacoste JM, Cordi A. (2000). S18616, a highly potent, spiroimidazoline agonist at 2-adrenoceptors: receptor profile, antinicieptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J. Pharmacol. Exp. Ther. 295:1192-1205.
  27. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Adhumeau A, Brocco M, Nicolas JP, Boutin JA, Despaux N, Peglion JL (2000). S18327 (1-{2-[4-(fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at 1-and 2-adreneric receptors : I. Receptorial, neurochemical and electrophysiological profile. J. Pharmacol. Exp. Ther. 292:38-53.
  28. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F (2000). Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blokade of 2-adrenergic receptors and serotonin2C receptors : A comparison with citalopram. Eur. J. Neurosciense. 12:1079-1095.
  29. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G (2000). S33084 ; a novel, potent, selective, and competitive antagonist at dopamine D3-receptor : I. receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293:1048-1062.
  30. Millan MJ, Newman-Tancredi A, Duqueyroix D, Cussac D (2001). Agonist properties of pindolol at h5 HT1A receptors coupled to Mitogen-Activated Protein Kinase Eur. J. Pharmacol. 424:13-17.
  31. Millan MJ, Newman-Tancredi A, Quentric Y, Cussac D (2001). The “selective” dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned, human serotonin2C receptors. Psychopharmacology 156:58-62.
  32. Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, Lejeune F, Rivet JM, Brocco M, Duqueyroix D, Dekeyne A, Nicolas JP, Boutin JA, Newman-Tancredi A (2001). Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human 2-adrenoceptors: cellular and functional characterisation. J. Pharmacol. Exp. Ther. 297:876-887.
  33. Newman-Tancredi A, Cussac D, Brocco M, Rivet JM, Chaput C, Touzard M, Pasteau V, Millan MJ (2001). Quinelorane-induced G-protein activation in caudate putamen via dopamine D2 –like receptors: effect of unilateral 6-hydroxy-dopamine substantia nigra lesions. Brain Research. 920:41-54.
  34. Audinot V, Newman-Tancredi A, Cussac D, Millan MJ (2001). Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5 HT)1B and h5 HT1D receptors Neuropsychopharmacol. 25:410-422.
  35. Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, Goldstein S, Millan MJ (2002). Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: Influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn-Schmiedeberg’s Arch. Pharmacol. 365:242-252.
  36. Cussac D, Duqueyroix D, Newman-Tancredi A, Millan MJ (2002). Stimulation by antipsychotic agents of Mitogen-Activated Protein Kinase (MAPK) coupled to cloned, human (h)serotonin (5 HT)1A receptors. Psychopharmacology. 162:168-177.
  37. Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ (2002). Differential activation of Gq/11 and Gi3 proteins at 5-HT2C receptors revealed by antibody capture assays: Influence of receptor reserve and relationship to agonist-directed trafficking. Molecular Pharmacology 62:578-589.
  38. Newman-Tancredi A, Cussac D, Marini L, Millan MJ (2002). Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT1A receptors-mediated Gi3 activation : Conformational selection by high efficacy agonists, and relationship to trafficking of receptor signalling. Molecular Pharmacology 62:590-601.
  39. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine “D2-like receptor” and 1 2-adrenoceptor. J. Pharmacol. Exp. Ther. 303:805-814.
  40. Newman- Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ (2002). Differential actions of antiparkinsonian agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5 HT1 and 5 HT2 receptor subtypes. J. Pharmacol. Exp. Ther. 303:815-822.
  41. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned, human receptor subtypes. J. Pharmacol. Exp. Ther. 303:791-804.
  42. Newman-Tancredi A, Cussac D, Marini L, Touzard M, Millan MJ (2003). h5-HT1B receptor-mediated constitutive Gi3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT. Br. J. Pharmacol. 138:1077-1084.
  43. Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ (2003). Comparison of hippocampal G-protein activation by 5-HT1A receptor agonists and the atypical antipsychotic, clozapine and S16924. Naunyn-Schmiedeberg’s Arch. Pharmacol 368:188-199.
  44. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (2003). The novel melatonin agonist, agomelatine (S20098), is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 306:954-964.
  45. Cussac D, Pasteau V, Millan MJ (2004). Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapine. Eur. J. Pharmacol. 485:111-117.
  46. Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M (2004). The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology 174:341-357.
  47. Millan MJ, Cussac D, Gobert A, Lejeune F, Rivet JM, Mannoury La Cour C, Newman-Tancredi A, Peglion JL (2004). S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular,electrophysiological, and neurochemical profile in comparison with ropinirole. J Pharmacol Exp Ther 309:903-920.
  48. Heusler P, Pauwels PJ, Wurch T, Newman-Tancredi A, Tytgat J, Colpaert FC, Cussac D (2005). Differential ion current activation by human 5-HT1A receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling. Neuropharmacology 49:963-976.
  49. Bruins Slot LA, De Vries L, Newman-Tancredi A, Cussac D (2006). Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534:63-70.
  50. De Vries L, Palmier C, Finana F, Le Grand B, Perez M, Cussac D (2006). Pharmacological characterization of protease activated receptor-1 by a serum responsive element-dependent reporter gene assay: Major role of calmodulin. Biochem Pharmacol 71:1449-1458.
  51. Mannoury la Cour C, Vidal S, Pasteau V, Cussac D, Millan MJ (2007). Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex: a scintillation proximity assay (SPA)/antibody-capture characterization of benzazepine agonists. Neuropharmacology 52:1003-1014.
  52. Martel JC, Ormière AM, Leduc N, Assié MB, Cussac D, Newman-Tancredi A (2007). Native rat hippocampal 5-HT1A receptors show constitutive activity. Mol Pharmacol. 71:638-643.
  53. Heusler P, Newman-Tancredi A, Castro-Fernandez A, Cussac D (2007). Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. Neuropharmacology 52:1106-1113.
  54. Newman-Tancredi A, Assié MB, Martel JC, Cosi C, Slot LB, Palmier C, Rauly-Lestienne I, Colpaert F, Vacher B, Cussac D (2007). F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile. Br J Pharmacol. 151:237-252.
  55. Bruins Slot LA, Palmier C, Tardif S, Cussac D (2007). Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.Neuropharmacology 53:232-241.
  56. Newman-Tancredi A, Cussac D, Depoortere R (2007). Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs. 8:539-554. Review.
  57. Rauly-Lestienne I, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Cussac D (2007). Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. Naunyn Schmiedebergs Arch Pharmacol. 376:93-105.
  58. Martel JC, Leduc N, Ormière AM, Faucillon V, Danty N, Culie C, Cussac D, Newman-Tancredi A (2007). WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. Eur J Pharmacol. 574:15-19.
  59. Pignier C, Revenaz C, Rauly-Lestienne I, Cussac D, Delhon A, Gardette J, Le Grand B (2007). Direct protective effects of poly-unsaturated fatty acids, DHA and EPA, against activation of cardiac late sodium current : A mechanism for ischemia selectivity. Basic Res Cardiol. 102:553-564.
  60. Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, Pasteau V, Boutin JA, Dubuffet T, Lavielle G (2008). S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther. 324:587-599
  61. Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N, Cussac D (2008). Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. Int J Neuropsychopharmacol. 11:293-307.
  62. Pinet C, Algalarrondo V, Sablayrolles S, Le Grand B, Pignier C, Cussac D, Perez M, Hatem SN, Coulombe A (2008). Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes.Mol Pharmacol. 73:1622-1631.
  63. Heusler P, Newman-Tancredi A, Loock T, Cussac D (2008). Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. Eur J Pharmacol. 581:37-46.
  64. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I (2008). Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 594: 32-38.
  65. Heusler P, Bruins Slot L, Rauly-Lestienne I, Palmier C, Tardif S, Tourette A, Ailhaud MC, Cussac D (2009). Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D(4.4) receptors: differential pathway-dependent potencies of receptor agonists. Naunyn Schmiedebergs Arch Pharmacol. 379:87-99.
  66. Buritova J, Berrichon G, Cathala C, Colpaert F, Cussac D (2009). Region-specific changes in 5-HT(1A) agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: A quantitative ELISA study.Neuropharmacology 56:350-361.
  67. Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B, Cussac D (2009). Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol.. 156:338-353.
  68. Martel JC, Assié MB, Bardin L, Depoortère R, Cussac D, Newman-Tancredi A (2009). 5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception. Br J Pharmacol. 158:232-242.
  69. Cussac D, Palmier C, Finana F, De Vries L, Tardif S, Léger C, Bernois S, Heusler P (2009). Mutant 5-Hydroxytryptamine1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology. J Pharmacol Exp Ther. 331:222-233.
  70. Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D (2009). F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Eur J Pharmacol. 620:27-35.
  71. Perez M, Lamothe M, Maraval C, Mirabel E, Loubat C, Planty B, Horn C, Michaux J, Marrot S, Letienne R, Pignier C, Bocquet A, Nadal-Wollbold F, Cussac D, de Vries L, Le Grand B (2009). Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. J Med Chem.52:5826-5836.
  72. De Vries L, Finana F, Cachoux F, Vacher B, Sokoloff P, Cussac D (2010). Cellular BRET assay suggests a conformational rearrangement of preformed TrkB/Shc complexes following BDNF-dependent activation. Cell Signal. 22:158-165.
  73. Vispé S, DeVries L, Créancier L, Besse J, Bréand S, Hobson DJ, Svejstrup JQ, Annereau JP, Cussac D, Dumontet C, Guilbaud N, Barret JM, Bailly C (2009). Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther. 8:2780-2790.
  74. Lauressergues E, Staels B, Valeille K, Majd Z, Hum DW, Duriez P, Cussac D (2010). Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol. 381:427-439.
  75. Heusler P, Rauly-Lestienne I, Tourette A, Tardif S, Ailhaud MC, Croville G, Cussac D (2010). Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist. Eur J Pharmacol. 640:8-14.
  76. Heusler P, Palmier C, Tardif S, Bernois S, Colpaert FC, Cussac D (2010). [(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand. Naunyn Schmiedebergs Arch Pharmacol. 382:321-330.
  77. Vacher B, Funes P, Chopin P, Cussac D, Heusler P, Tourette A, Marien M (2010). Rigid analogues of the α2-adrenergic blocker atipamezole: small changes, big consequences. J Med Chem. 53:6986-6995.
  78. Rauly-Lestienne I, Lestienne F, Ailhaud MC, Binesse J, Newman-Tancredi A, Cussac D (2011). Competitive interaction of 5-HT(1A) receptors with G-protein subtypes in CHO cells demonstrated by RNA interference. Cell Signal. 23:58-64.
  79. Lauressergues E, Martin F, Helleboid A, Bouchaert E, Cussac D, Bordet R, Hum D, Luc G, Majd Z, Staels B, Duriez P (2011). Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. Naunyn Schmiedebergs Arch Pharmacol. 383:423-436.
  80. Heusler P, Bruins Slot L, Tourette A, Tardif S, Cussac D (2011). The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human dopamine D(2) and serotonin 5-HT(1A) receptors. Eur J Pharmacol. 669(1-3):51-58.
  81. Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G (2012). S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J Pharmacol Exp Ther. 340:750-764.
  82. Lauressergues E, Bert E, Duriez P, Hum D, Majd Z, Staels B, Cussac D (2012). Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation? Neuropharmacology 62:784-796.
  83. Cussac D, Rauly-Lestienne I, Heusler P, Finana F, Cathala C, Bernois S, De Vries L (2012). μ-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways. Cell Signal. 24:1648-1657.
  84. Auclair AL, Martel JC, Assié MB, Bardin L, Heusler P, Cussac D, Marien M, Newman-Tancredi A, O’Connor JA, Depoortère R (2013). Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 70:338-347.
  85. Heusler P, Tourette A, Cussac D (2015). Potencies and unblocking kinetic properties of antagonists at recombinant human NMDA receptors in a Xenopus oocytes model. Naunyn Schmiedebergs Arch Pharmacol. 388:509-516.
  86. Vispé S, Deroide A, Davoine E, Desjobert C, Lestienne F, Fournier L, Novosad N, Bréand S, Besse J, Busato F, Tost J, De Vries L, Cussac D, Riond J, Arimondo PB (2015). Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2′-deoxycytidine in human leukemic KG1 cells. Oncotarget. 6(17):15265-15282.
  87. Heusler P, Cussac D, Naline E, Tardif S, Clerc T, Devillier P (2015). Characterization of V0162, a new long-acting antagonist at human M3 muscarinic acetylcholine receptors. Pharmacol. Research 100:117-126.
  88. Heusler P, Tardif S, Cussac D (2016). Agonist stimulation at human μ opioid receptors in a [(35)S]GTPγS incorporation assay: observation of « bell-shaped » concentration-response relationships under conditions of strong receptor G protein coupling. J. Receptor Signal Transduction 36(2):158-166.
  89. Lauressergues E, Heusler P, Lestienne F, Troulier D, Rauly-Lestienne I, Tourette A, Ailhaud MC, Cathala C, Tardif S, Denais-Laliève D, Calmettes MT, Degryse AD, Dumoulin A, De Vries L, Cussac D (2016). Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model. Pharmaco Res Perspect. 4(2):e00214.
  90. Rauly-Lestienne I, Heusler P, Cussac D, Lantoine-Adam F, de Almeida Cyrino FZG, Bouskela E (2017). Contribution of muscarinic receptors to in vitro and in vivo effects of Ruscus extract. Microvasc Res. 114:1-11.
  91. Newman-Tancredi A, Martel JC, Cosi C,  Heusler P, Lestienne F, Varney MA, Cussac D  (2017). Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist. J Pharm Pharmacol. 69(9):1178-1190.
  92.  De Vries L, Finana F, Cathala C, Ronsin B, Cussac D (2019) Innovative bioluminescence Energy transfert assay reveals differential agonist-induced D2 receptor intracellular trafficking and arrestin-3 recruitment. Mol Pharmacol. 96: 308-319
  93. Newman-Tancredi A, Cussac D, Ormière AM, Lestienne F, Varney MA, Martel JC (2019) Bell-shaped agonist activation of 5-HT1A receptor-coupled to Gαi3 G-proteins: Receptor density-dependent switch in receptor signaling. Cell Signal. 63:109383. doi: 10.1016/j.cellsig.2019.109383. Epub 2019 Jul 31.